Is 0512.HK overvalued or undervalued?

0512.HK currently has a P/E ratio of 14.79. Relative to the sector average of 15.80, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Grand Pharmaceutical Group Limited stock?

Grand Pharmaceutical Group Limited trades on HKSE. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 0512.HK?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 0512.HK protect my money against local inflation?

Many investors in Latin America buy international stocks like 0512.HK to protect their purchasing power. Because 0512.HK is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 0512.HK shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 0512.HK a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 0512.HK diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks0512.HK

Grand Pharmaceutical Group Limited

HK$4.74+HK$0.00+0.00%

HKSE / HKD

Market cap

HK$16.6B

P/E

14.8

EPS (TTM)

HK$0.04

Dividend yield

3.57%

Beta

0.70

1Y return

-43.50%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$1.1B2021

$1.2B2022

$1.3B2023

$1.5B2024

$1.6B2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.29Low
Current ratio1.34
Cash ratio0.11
Net margin9.0%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

0512.HK14.8
Healthcare sector median15.8
S&P 50022.0

Trades about 6% below its sector, cheaper than its peers on earnings.

Ratios

PEG-0.32
Price to book0.96
EPS (TTM)HK$0.04
Payout ratio5,293%
FCF yield2.82%

Range & risk

HK$4.53HK$8.97

Trading in the lower third of its 52-week band

Beta0.70

Profile

What Grand Pharmaceutical Group Limited actually does

Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series products. In addition, the company provides bio-pesticides and additives; disposal surgical products; and Chinese medicine and health food products, as well as engages in the treatment of sewage. The company has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company has a business collaboration with the Sirtex Group agreement to enable collaboration on research and development of pharmaceutical products. The company has a strategic partnership with the University of Hong Kong for the research and development of drugs in the field of anti-infection and the industrialization of the research results. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited. The company was incorporated in 1995 and is based in Central, Hong Kong.

CEO

Chao Zhou

Employees

12,614

Headquarters

Hong Kong

Founded

2004-05-11

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 0512.HK and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

0512.HK has a beta of 0.70, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

Grand Pharmaceutical Group Limited